Hospital
Saint Thomas Rutherford Hospital
Saint Thomas Rutherford Hospital was paid $16.20M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99283, emergency room visit (moderate) — 41% of everything it billed.
33Billing provider infoSAINT THOMAS RUTHERFORD HOSPITAL
MURFREESBORO, TN 37129
MURFREESBORO, TN 37129
33aNPI1164590386assigned 12/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.20M
24GClaims289,365
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#17 of 71
Median peer was paid$6.96M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,972 | $2.71M | |
| 2019 | 49,336 | $2.89M | |
| 2020 | 32,517 | $1.75M | |
| 2021 | 38,800 | $2.23M | |
| 2022 | 48,532 | $2.66M | |
| 2023 | 53,980 | $2.73M | |
| 2024incomplete | 18,228 | $1.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 41% | 52,853 | 49,123 | $6.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 39% | 42,246 | 38,188 | $6.37M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.1% | 20,860 | 18,632 | $831K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 6,492 | 6,183 | $602K |
| G0378 | Hospital observation service, per hour | 2.9% | 4,673 | 3,291 | $477K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.4% | 882 | 720 | $220K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 5,012 | 4,776 | $202K |
| 59025 | Fetal non-stress test | <1% | 1,702 | 1,161 | $146K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,728 | 4,468 | $124K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,457 | 5,933 | $95K |
| 85027 | <1% | 32,046 | 28,335 | $70K | |
| 84484 | <1% | 9,485 | 7,706 | $65K |
63 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 4,090 | $58K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,192 | $53K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 734 | $45K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28,049 | $40K |
| 84703 | <1% | 10,240 | $29K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 70 | $22K |
| 80053 | Comprehensive metabolic panel | <1% | 8,271 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,888 | $15K |
| 81001 | <1% | 8,881 | $12K | |
| 97597 | <1% | 356 | $11K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 150 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 912 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 486 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 44 | $8K |
| 83690 | <1% | 2,681 | $7K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 77 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 580 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 160 | $6K |
| 93976 | <1% | 113 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,501 | $5K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 18 | $5K |
| 93017 | <1% | 109 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 162 | $2K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 33 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 44 | $1K |
| 77336 | <1% | 23 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 827 | $959.07 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 25 | $844.55 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 221 | $745.57 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 450 | $508.00 |
| 96376 | <1% | 120 | $461.88 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 64 | $263.92 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 90 | $199.68 |
| 87070 | <1% | 84 | $187.42 | |
| 81003 | <1% | 494 | $170.95 | |
| 80061 | Lipid panel | <1% | 36 | $168.75 |
| 83735 | <1% | 56 | $147.16 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 14 | $143.50 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,065 | $123.28 |
| 86850 | <1% | 96 | $39.10 | |
| 83880 | <1% | 20 | $36.85 | |
| 80076 | <1% | 48 | $26.28 | |
| 86900 | <1% | 99 | $15.14 | |
| 86901 | <1% | 99 | $15.14 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12 | $12.18 |
| 85610 | <1% | 87 | $11.94 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 61 | $4.75 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 425 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 25 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 23 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 21 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 15 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 450 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 801 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,031 | $0.00 |
| A9270 | Non-covered item or service | 0% | 45 | $0.00 |
| J3490 | Unclassified drugs | 0% | 40 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 17 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 17 | $0.00 |
| 85379 | 0% | 13 | $0.00 | |
| C1769 | Guide wire | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFERGUSON, GORDON (PRESIDENT AND CEO)
Parent organizationSAINT THOMAS HEALTH SERVICES